Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1216-1236
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1216
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1216
Table 1 Comparison of RON and PD-L1 expression and clinicopathological characteristics of patients with colorectal cancer in the FAHZUSM and Gene Expression Omnibus cohorts, n (%)
FAHZUSM cohort (n = 381) | GEO cohort (n = 287) | ||||||||||||||||
Characteristic | Cases | RON expression | PD-L1 expression | Cases No (%) | RON expression | PD-L1 expression | |||||||||||
Low | High | 1P value | Low | High (TIMC) | 2P value | Low | High (TC) | 3P value | Low | High | 1P value | Low | High (TC) | 3P value | |||
No. of cases number | 381 | 260 | 121 | 247 | 91 | 247 | 43 | 287 | 193 | 94 | 48 | 239 | |||||
Age (mean ± SD) | 61.16 ± 12.419 | 60.40 ± 12.560 | 62.81 ± 11.997 | 0.859 | 60.94 ± 12.37 | 62.04 ± 13.080 | 0.771 | 60.94 ± 12.37 | 61.16 ± 12.419 | 0.938 | 68.44 ± 14.00 | 66.87 ± 13.18 | 71.65 ± 15.12 | 0.006 | 66.94 ± 14.33 | 68.74 ± 13.95 | 0.417 |
Sex | |||||||||||||||||
Man | 215 (56.4) | 157 (60.4) | 58 (47.9) | 0.023 | 143 (57.9) | 54 (59.3) | 0.811 | 143 (57.9) | 18 (41.9) | 0.051 | 158 (55.1) | 111 (57.5) | 47 (50) | 0.230 | 30 (62.5) | 128 (53.6) | 0.256 |
Women | 166 (43.6) | 103 (39.6) | 63 (52.1) | 104 (42.1) | 37 (40.7) | 104 (42.1) | 25 (58.1) | 129 (44.9) | 82 (42.5) | 47 (50) | 18 (37.5) | 111 (46.4) | |||||
Principal diagnosis | |||||||||||||||||
Rectum | 229 (60.1) | 158 (61.1) | 71 (58.7) | 0.698 | 153 (61.9) | 47 (51.6) | 0.088 | 153 (61.9) | 29 (67.4) | 0.491 | 165 (57.5) | 111 (57.5) | 54 (57.4) | 0.920 | 34 (70.8) | 131 (54.8) | 0.040 |
Colon | 152 (39.9) | 102 (38.9) | 50 (41.3) | 94 (38.1) | 44 (48.4) | 94 (38.1) | 14 (32.6) | 122 (42.5) | 82 (42.5) | 40 (42.6) | 14 (29.2) | 108 (45.2) | |||||
Pathological grade | |||||||||||||||||
Well/moderate | 9 (2.4) | 6 (2.3) | 3 (2.5) | 0.177 | 5 (2) | 3 (3.3) | 0.778 | 5 (2) | 1 (2.3) | 0.898 | NA | ||||||
Poor | 346 (90.8) | 232 (89.2) | 114 (94.2) | 224 (90.7) | 82 (90.1) | 224 (90.7) | 40 (93) | ||||||||||
Unknown | 26 (6.8) | 22 (8.5) | 4 (3.3) | 18 (7.1) | 6 (6.3) | 18 (7.3) | 2 (4.7) | ||||||||||
T stage | |||||||||||||||||
Tis-T2 | 107 (28.1) | 85 (32.7) | 22 (18.2) | 0.001 | 73 (29.6) | 23 (25.3) | 0.105 | 73 (29.6) | 11 (25.6) | 0.864 | 28 (9.7) | 18 (9.3) | 10 (10.6) | 0.459 | 3 (6.3) | 25 (10.5) | 0.437 |
T3 | 177 (46.5) | 121 (46.5) | 56 (46.3) | 118 (47.8) (46.8%) | 37 (40.7) | 118 (47.8) | 22 (51.2) | 208 (72.5) | 144 (74.6) | 64 (68.1)20 | 39 (81.3) | 169 (70.7) | |||||
T4 | 97 (25.5) | 54 (20.8) | 43 (35.5) | 56 (22.7) | 31 (34.1) | 56 (22.7) | 10 (23.3) | 51 (17.8) | 31 (16.1) | 20 (21.3) | 6 (12.5) | 45 (18.8) | |||||
N stage | |||||||||||||||||
N0 | 251 (65.9) | 184 (70.8) | 67 (55.4) | 0.003 | 164 (66.4) | 62 (68.1) | 0.764 | 164 (66.4) | 25 (58.1) | 0.294 | 141 (49.1) | 97 (50.3) | 44 (46.8) | 0.583 | 27 (56.3) | 114 (44.7) | 0.279 |
N (1-2) | 91 (23.9) | 76 (29.2) | 54 (44.6) | 83 (33.6) | 29 (31.9) | 83 (33.6) | 12 (27.9) | 146 (50.9) | 96 (49.7) | 50 (53.2) | 21 (43.7) | 125 (52.3) | |||||
M stage | |||||||||||||||||
M0 | 368 (96.6) | 252 (96.9) | 116 (95.9) (96.3%) | 0.822 | 241 (97.6) | 85 (93.4) | 0.133 | 241 (97.6) | 42 (97.7) | 1.000 | 268 (93.4) | 183 (94.8) | 85 (90.4) | 0.160 | 47 (97.9) | 221 (92.5) | 0.216 |
M1 | 13 (3.4) | 8 (3.1) | 5 (4.1) | 6 (2.4) | 6 (6.6) | 6 (2.4) | 1 (2.3) | 19 (6.6) | 10 (5.2) | 9 (9.6) | 1 (2.1) | 18 (7.5) | |||||
Disease stage | |||||||||||||||||
0-II | 246 (64.6) | 180 (69.2) | 66 (54.5) | 0.016 | 162 (65.6) | 59 (64.8) | 0.897 | 162 (65.6) | 25 (58.1) | 0.346 | 139 (48.4) | 95 (49.2) | 44 (46.8) | 0.701 | 27 (56.3) | 112 (46.9) | 0.235 |
III-IV | 135 (35.4) | 80 (30.8) | 55 (45.5) | 85 (34.4) | 32 (35.2) | 85 (34.4) | 18 (41.9) | 148 (51.6) | 98 (50.8) | 50 (53.2) | 21 (43.8) | 127 (53.1) | |||||
Histological type | |||||||||||||||||
Adenocarcinoma | 335 (87.9) | 227 (87.3) | 108 (89.3) | 0.706 | 214 (86.6) | 84 (92.3) | 0.130 | 214 (86.6) | 37 (86) | 0.488 | 287 (100) | 193 (100) | 94 (100) | 48 (100) | 239 (100) | ||
Mucinous/SRCC | 36 (9.4) | 25 (9.6) | 11 (9.1) | 28 (11.3) | 4 (4.4) | 28 (11.3) | 4 (9.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Other | 10 (2.6) | 8 (3.1) | 2 (1.7) | 5 (2.0) | 3 (3.3) | 5 (2.0) | 2 (4.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||||
Treatment | |||||||||||||||||
Yes | 173 (45.4) | 110 (42.3) | 63 (52.1) | 0.043 | 112 (45.3) | 38 (41.8) | 0.694 | 112 (45.3) | 23 (32.6) | 0.472 | 115 (40.1) | 89 (46.1) | 26 (27.7) | 0.003 | 22 (45.8) | 93 (38.9) | 0.372 |
No | 158 (41.5) | 119 (45.8) | 39 (32.2) | 105 (42.5) | 39 (42.9) | 105 (42.5) | 14 (53.5) | 172 (59.9) | 104 (53.9) | 68 (72.3) | 26 (54.2) | 146 (61.1) | |||||
Unknown | 50 (13.1) | 31 (11.9) | 19 (15.7) | 30 (12.1) | 14 (15.4) | 30 (12.1) | 6 (14) | 0 (0) | 0 (0) | ||||||||
PD-L1 (protein) | |||||||||||||||||
Low | 247 (64.8) | 177 (73.1) | 70 (26.9) | 0.9764 | NA | ||||||||||||
High (TIMCs) | 91 (23.9) | 65 (26.9) | 26 (27.1) | ||||||||||||||
High (TCs) | 43 (11.3) | 18 (9.2) | 25 (26.3) | < 0.0015 | |||||||||||||
PD-L1 (mRNA) | |||||||||||||||||
Low | NA | 48 (16.7) | 31 (16.1) | 17 (18.1) | 0.666 | ||||||||||||
High | 239 (83.3) | 162 (83.9) | 77 (81.9) |
- Citation: Liu YZ, Han DT, Shi DR, Hong B, Qian Y, Wu ZG, Yao SH, Tang TM, Wang MH, Xu XM, Yao HP. Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer. World J Gastrointest Oncol 2020; 12(11): 1216-1236
- URL: https://www.wjgnet.com/1948-5204/full/v12/i11/1216.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i11.1216